A mechanism, with a limit at each step
Conceptual relationships only; not a dose or symptom decision tool.
| Concept | What it tells us |
|---|---|
| Smoke | May induce selected enzymes |
| Clearance | Some medicines can be processed differently |
| Individual care | Cannot be calculated from the mechanism |
Smoke is the relevant exposure in this mechanism
Enzyme induction means that exposure increases the activity of an enzyme involved in processing a medicine. Tobacco smoke can induce CYP1A2, one such pathway. With some interacting medicines, faster metabolism can mean lower blood concentrations; removing the smoke exposure can change that pathway again.
The SPS guidance distinguishes smoke constituents from nicotine. Nicotine replacement does not reproduce this particular smoke-driven enzyme effect. That distinction is not a claim that every nicotine product is harmless or free of every possible interaction.
Two named medicines do not define a whole category
NICE names clozapine and olanzapine among medicines affected by smoking changes. The EMA olanzapine product information describes CYP1A2 metabolism and differences between smoking and non-smoking groups. It also notes substantial overall variation between individuals. A group average is not a prediction for a particular person.
The enzyme involved, the medicine's other elimination pathways and individual circumstances matter. Having a psychiatric prescription alone does not establish the same interaction for everyone. This page gives neither a cigarette threshold nor a timetable, percentage or formula for changing a medicine.
A mechanism is not a diagnosis or a treatment plan
Tell the existing prescribing team or pharmacist about a change in smoking status. Drug concentration, clinical effect and how someone feels are different things. The mechanism alone cannot assign the cause of a new change or decide a treatment response. The prescribing team and pharmacist interpret the actual medicine and situation; cessation support has a separate behavioural role. NICE also recognises tailored cessation support for people with severe mental-health conditions who need additional help.
Do not change psychiatric medicines on the basis of this explanation. Seek qualified local care for concerns; immediate danger or inability to stay safe needs local urgent or emergency help, not a routine cessation appointment.
Sources
The central claims on this page were checked against the sources below.
- NHS Specialist Pharmacy Service (United Kingdom): Smoke constituents and drug metabolism (published 2023; mechanism sections)
Sources checked: 2026-10-12
- European Medicines Agency: Olanzapine: sections 4.5 and 5.2 on metabolism and individual variability
Sources checked: 2026-10-12
- NICE (United Kingdom): Mental-health cessation support and named medicine interactions
Sources checked: 2026-10-12
General mechanism education, not symptom attribution, monitoring instructions or psychiatric treatment adjustment.